330 related articles for article (PubMed ID: 33681389)
21. Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis.
Freitas CS; Oliveira-da-Silva JA; Lage DP; Costa RR; Mendonça DVC; Martins VT; Reis TAR; Antinarelli LMR; Machado AS; Tavares GSV; Ramos FF; Coelho VTS; Brito RCF; Ludolf F; Chávez-Fumagalli MA; Roatt BM; Ramos GS; Munkert J; Ottoni FM; Campana PRV; Humbert MV; Coimbra ES; Braga FC; Pádua RM; Coelho EAF
Parasitol Res; 2021 Jan; 120(1):321-335. PubMed ID: 33191446
[TBL] [Abstract][Full Text] [Related]
22. Cinnamomum cassia exhibits antileishmanial activity against Leishmania donovani infection in vitro and in vivo.
Afrin F; Chouhan G; Islamuddin M; Want MY; Ozbak HA; Hemeg HA
PLoS Negl Trop Dis; 2019 May; 13(5):e0007227. PubMed ID: 31071090
[TBL] [Abstract][Full Text] [Related]
23. Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
Pereira IAG; Mendonça DVC; Tavares GSV; Lage DP; Ramos FF; Oliveira-da-Silva JA; Antinarelli LMR; Machado AS; Carvalho LM; Carvalho AMRS; Salustiano IV; Reis TAR; Bandeira RS; Silva AM; Martins VT; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Duarte MC; Menezes-Souza D; Coimbra ES; Leite JPV; Coelho EAF; Gonçalves DU
Parasite Immunol; 2020 Dec; 42(12):e12784. PubMed ID: 32772379
[TBL] [Abstract][Full Text] [Related]
24. Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis.
Kaur G; Chauhan K; Kaur S
Parasitology; 2019 Sep; 146(11):1440-1450. PubMed ID: 31104636
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of lapachol on treatment of cutaneous and visceral leishmaniasis.
Araújo IAC; de Paula RC; Alves CL; Faria KF; Oliveira MM; Mendes GG; Dias EMFA; Ribeiro RR; Oliveira AB; Silva SMD
Exp Parasitol; 2019 Apr; 199():67-73. PubMed ID: 30797783
[TBL] [Abstract][Full Text] [Related]
27. Curative efficacy of purified serine protease inhibitor PTF3 from potato tuber in experimental visceral leishmaniasis.
Paik D; Pramanik PK; Chakraborti T
Int Immunopharmacol; 2020 Aug; 85():106623. PubMed ID: 32504996
[TBL] [Abstract][Full Text] [Related]
28. Investigation of 8-methoxy-3-(4-nitrobenzoyl)-6-propyl-2H-chromen-2-one as a promising coumarin compound for the development of a new and orally effective antileishmanial agent.
de Figueiredo Peloso E; Merli RJ; Espuri PF; Nunes JB; Colombo FA; Sierra EJT; de Paulo DC; Dos Santos MH; Carvalho DT; Marques MJ
Mol Biol Rep; 2020 Nov; 47(11):8465-8474. PubMed ID: 33021720
[TBL] [Abstract][Full Text] [Related]
29. Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.
Deep DK; Singh R; Kulshrestha A; Wajid S; Salotra P
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297367
[TBL] [Abstract][Full Text] [Related]
30. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
31. Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo.
Kar A; Jayaraman A; Charan Raja MR; Srinivasan S; Debnath J; Mahapatra SK
Int Immunopharmacol; 2021 Feb; 91():107291. PubMed ID: 33360084
[TBL] [Abstract][Full Text] [Related]
32. Functionalized 1,2,3-triazolium salts as potential agents against visceral leishmaniasis.
das Chagas Almeida A; Meinel RS; Leal YL; Silva TP; Glanzmann N; Mendonça DVC; Perin L; Cunha-Júnior EF; Coelho EAF; Melo RCN; da Silva AD; Coimbra ES
Parasitol Res; 2022 May; 121(5):1389-1406. PubMed ID: 35169883
[TBL] [Abstract][Full Text] [Related]
33. Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential.
Ribeiro JM; Rodrigues-Alves ML; Oliveira E; Guimarães PPG; Maria Murta Santi A; Teixeira-Carvalho A; Murta SMF; Peruhype-Magalhães V; Souza-Fagundes EM
Int Immunopharmacol; 2022 Sep; 110():108952. PubMed ID: 35716482
[TBL] [Abstract][Full Text] [Related]
34. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Costa RR; Oliveira-da-Silva JA; Reis TAR; Tavares GSV; Mendonça DVC; Freitas CS; Lage DP; Martins VT; Antinarelli LMR; Machado AS; Bandeira RS; Ludolf F; Santos TTO; Brito RCF; Humbert MV; Menezes-Souza D; Duarte MC; Chávez-Fumagalli MA; Roatt BM; Coimbra ES; Coelho EAF
Med Microbiol Immunol; 2021 Jun; 210(2-3):133-147. PubMed ID: 33870453
[TBL] [Abstract][Full Text] [Related]
35. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
36. Activity and Cell-Death Pathway in
Scariot DB; Volpato H; Fernandes NS; Soares EFP; Ueda-Nakamura T; Dias-Filho BP; Din ZU; Rodrigues-Filho E; Rubira AF; Borges O; Sousa MDC; Nakamura CV
Front Cell Infect Microbiol; 2019; 9():208. PubMed ID: 31259161
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo antileishmanial efficacy of nitazoxanide against Leishmania donovani.
Zhang R; Shang L; Jin H; Ma C; Wu Y; Liu Q; Xia Z; Wei F; Zhu XQ; Gao H
Parasitol Res; 2010 Jul; 107(2):475-9. PubMed ID: 20495931
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Ursolic Acid on Leishmania (Leishmania) amazonensis Is Related to Programed Cell Death and Presents Therapeutic Potential in Experimental Cutaneous Leishmaniasis.
Yamamoto ES; Campos BL; Jesus JA; Laurenti MD; Ribeiro SP; Kallás EG; Rafael-Fernandes M; Santos-Gomes G; Silva MS; Sessa DP; Lago JH; Levy D; Passero LF
PLoS One; 2015; 10(12):e0144946. PubMed ID: 26674781
[TBL] [Abstract][Full Text] [Related]
39. Imaging visceral leishmaniasis in real time with golden hamster model: Monitoring the parasite burden and hamster transcripts to further characterize the immunological responses of the host.
Rouault E; Lecoeur H; Meriem AB; Minoprio P; Goyard S; Lang T
Parasitol Int; 2017 Feb; 66(1):933-939. PubMed ID: 27794505
[TBL] [Abstract][Full Text] [Related]
40. Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: The in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of cell cycle control.
Antinarelli LMR; Midlej V; da Silva EDS; Coelho EAF; da Silva AD; Coimbra ES
Chem Biol Interact; 2023 Feb; 371():110333. PubMed ID: 36592711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
